Fulgent Genetics/$FLGT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Fulgent Genetics
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
Ticker
$FLGT
Sector
Primary listing
Employees
1,315
Headquarters
Website
Fulgent Genetics Metrics
BasicAdvanced
$521m
-
-$2.40
0.88
-
Price and volume
Market cap
$521m
Beta
0.88
52-week high
$31.04
52-week low
$13.46
Average daily volume
533k
Financial strength
Current ratio
5.315
Quick ratio
3.906
Long term debt to equity
0.717
Total debt to equity
0.974
Interest coverage (TTM)
-1,299.99%
Profitability
EBITDA (TTM)
-77.195
Gross margin (TTM)
38.71%
Net profit margin (TTM)
-23.04%
Operating margin (TTM)
-31.65%
Effective tax rate (TTM)
11.00%
Revenue per employee (TTM)
$240,000
Management effectiveness
Return on assets (TTM)
-5.37%
Return on equity (TTM)
-6.92%
Valuation
Price to revenue (TTM)
1.764
Price to book
0.5
Price to tangible book (TTM)
0.63
Price to free cash flow (TTM)
-4.992
Free cash flow yield (TTM)
-20.03%
Free cash flow per share (TTM)
-3.676
Growth
Revenue change (TTM)
9.54%
Earnings per share change (TTM)
79.60%
3-year revenue growth (CAGR)
-4.25%
10-year revenue growth (CAGR)
39.56%
3-year earnings per share growth (CAGR)
40.31%
10-year earnings per share growth (CAGR)
36.48%
What the Analysts think about Fulgent Genetics
Analyst ratings (Buy, Hold, Sell) for Fulgent Genetics stock.
Fulgent Genetics Financial Performance
Revenues and expenses
Fulgent Genetics Earnings Performance
Company profitability
Fulgent Genetics News
AllArticlesVideos
Fulgent Presents Updated FID-007 Data at ASCO 2026
Business Wire·2 weeks ago
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
Business Wire·4 weeks ago
Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs